This biotech firm has room to run, even as its drug royalties are set to shrink
- Posted on April 14, 2026
- By CNBC
- 0 Views
This biotech firm has room to run, even as its drug royalties are set to shrink
Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will support its growth, per Piper Sandler.
